glp-1 and type 1 diabetes for Weight Loss Improved Heart and Kidney Outcomes

Keep out of the reach of children

GLP-1 receptor agonists like Ozempic and Wegovy are changing the game when it comes to diabetes and weight management

Adoption remained modest until recent years as GLP-1 drug claims rose from 6.9 percent in 2023 to 10.5 percent in 2025

However, it can amplify side effects like nausea, restlessness, and dehydration

This approach would effectively impact the current treatment of obesity and potentially even diabetes with GLP-1RAs, eliminating concerns related to needle phobia, pain, cost and the need for frequent dosing typically involved with the four weekly injections required over the course of one month